Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of C144-LS and C135-LS in Healthy Volunteers
NCT04700163Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of crexavibart and BMS-986414 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by The Rockefeller University. Primary endpoints: Grade 2 and Higher Adverse Events at 4 weeks, Grade 3 and Higher Adverse Events at 4 weeks and 4 more. Started Jan 2021; status: completed.
02
Drugs
crexavibartBMS-986414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04700163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700163.